Stay updated with the latest developments in the field of Muscle Dystrophy through these recent news articles
Please click on the provided links to access the full articles and stay informed about the current trends, breakthroughs, and research in the field of Muscle Dystrophy.
Atamyo Therapeutics a clinical-stage biotechnology company focused on the development of new generation gene therapies targeting muscular dystrophies and cardiomyopathies, today announced the dosing with ATA-200 gene therapy of first two patients in a phase 1b/2 clinical study in γ-sarcoglycan related limb-girdle muscular dystrophy Type 2C/R5 (LGMD2C/R5). LGMD2C/R5 affects children and leads to loss of ambulation before adulthood.
the House of Representatives’ Energy and Commerce Health Subcommittee voted to advance several bipartisan bills important to the rare disease community, two of which encourage rare disease drug development and two that would make it easier for many rare disease patients to access necessary care.
Genethon announced today the first positive clinical results obtained with the on-going ATA-001 Phase 1b/2b gene therapy clinical trial for the treatment of fukutin-related protein (FKRP) limb-girdle muscular dystrophy (LGMD2I/R9).
